Poison Center Calls for GLP-1 Weight Loss Drugs Surged After FDA Approval | Research

The takeaway

U.S. poison center reports for GLP-1 receptor agonists more than doubled after semaglutide's 2021 weight loss approval, with semaglutide accounting for 64% of post-approval cases and call volumes rising 9.9% per quarter.

10,033 exposures reported
Total GLP-1 receptor agonist cases reported to U.S. poison centers from 2012-2023, with volumes more than doubling after semaglutide's 2021 weight loss approval

What the researchers found

Over 10,033 GLP-1 receptor agonist exposures were reported to U.S. poison centers from 2012 to 2023. After semaglutide's weight loss approval in July 2021, case volumes more than doubled (3,113 pre-approval vs. 6,920 post-approval). Semaglutide became the dominant agent, accounting for 64.2% of post-approval reports.

The exposed population shifted younger and more female, consistent with the drug's new weight loss demographic. Most cases involved unintentional therapeutic errors with mild gastrointestinal symptoms. However, the proportion of cases requiring healthcare facility involvement increased significantly from 23.0% to 33.5% (RR = 1.46, p < 0.001). Segmented Poisson regression showed semaglutide exposures increased an additional 9.9% per quarter after approval.

Why it matters

Millions of people worldwide are now taking GLP-1 drugs for weight loss, and the rapid adoption has outpaced safety education. This study provides the first national-level picture of how that expansion has translated into real-world safety events. While most incidents are mild, the increase in healthcare visits suggests many people are confused about dosing or side effects — a problem that better patient counseling could address.

How the study worked

The researchers analyzed all human GLP-1 receptor agonist exposures reported to the National Poison Data System (NPDS) from 2012 to 2023. They used July 1, 2021 (semaglutide's weight loss approval date) to divide data into pre- and post-approval periods. Demographics, exposure characteristics, treatments, and outcomes were compared using standardized statistical tests. Quarterly call volumes were modeled using segmented Poisson regression to quantify changes in reporting trends.

What this study cannot tell us

Poison center data captures only voluntarily reported cases, likely underestimating the true number of exposures. The study cannot distinguish whether increased reporting reflects more actual incidents or greater awareness of poison centers. The data does not include cases managed entirely by healthcare providers without poison center involvement. The observational design cannot establish causation between the FDA approval and increased exposures — other factors like media coverage and off-label use may have contributed.

How to read the evidence

This is a large retrospective epidemiological study using national poison center surveillance data spanning 12 years. The dataset is comprehensive and the statistical methods are robust, but it is observational and limited to voluntarily reported cases. It provides strong population-level trend data but cannot establish causation.

When this study was published

Published in 2026, this study provides the most current national-level analysis of GLP-1 receptor agonist safety trends, covering data through 2023.

The bigger picture

This study reflects the broader public health implications of the GLP-1 drug boom. As medications like semaglutide and tirzepatide reach tens of millions of new users — many of whom have never used injectable medications before — the potential for dosing errors and unnecessary emergency visits grows. The findings underscore the need for healthcare systems to adapt their patient education and poison control guidance to match the scale of GLP-1 adoption.

Questions still open

What specific types of dosing errors are most common with GLP-1 receptor agonists, and could improved packaging or delivery device design reduce them?
How do poison center exposure rates for GLP-1 drugs compare to other widely prescribed medication classes that underwent similar rapid adoption?
Would targeted pharmacist counseling at the point of dispensing measurably reduce therapeutic error rates?

Common questions

Why are more people accidentally misusing GLP-1 weight loss drugs?

The rapid expansion of semaglutide use for weight loss brought in millions of new patients, many unfamiliar with injectable medications or dose titration schedules. Most poison center calls involved unintentional therapeutic errors — like taking the wrong dose or injecting at the wrong time — rather than intentional misuse. Better patient education at the point of prescribing could prevent many of these incidents.

Are GLP-1 drug overdoses dangerous?

According to this study, most GLP-1 receptor agonist exposures reported to poison centers involved mild symptoms, primarily gastrointestinal effects like nausea and vomiting. However, the proportion of cases that ended up at a healthcare facility increased after semaglutide's weight loss approval, suggesting that while outcomes are generally mild, the safety events shouldn't be dismissed.

Read the original research

National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.

Journal of medical toxicology : official journal of the American College of Medical Toxicology

View on PubMed ↗Publisher’s paper ↗

Citation

Miller, Jordan; Miller, Robert; Varney, Shawn M; Han, David. (2026). National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.. Journal of medical toxicology : official journal of the American College of Medical Toxicology. https://doi.org/10.1007/s13181-026-01121-z